US 2026/0209277 A1 · COMPOUNDS FOR RNA STABILISATION AND DELIVERY

Abstract

The present invention relates to a peptide-based compound for complexing and stabilizing a double stranded oligonucleotide, the compound comprising a structure p-x-b-x′-p′; wherein: i. p and p′ each refer to an oligonucleotide-binding motif; ii. x and x′ each refer to an optional linker motif, and iii. b is a linking motif coupling the oligonucleotide-binding motif to form a dimerized form, wherein motif p and p′ each independently represent a peptide chain having the following fragment comprising a contiguous sequence of at least 14 amino acid residues, and having the following general sequence (I), wherein the N-terminal position 1 is located on the left side: wherein “v” represents a variable amino acid residue position, and wherein “+” represents a positively charged amino acid residue.

Claims18

Dependent claims

1-36. (canceled)

A peptide-based compound comprising a structure p-x-b-x′-p′, wherein

i each of p and p′ is independently an oligonucleotide-binding motif;
ii each of x and x′ is independently an optional linker motif, and
iii b is a linking motif coupling the oligonucleotide-binding motifs to form a dimerized form,
wherein each of motif p and p′ is independently a peptide chain having the following fragment comprising a contiguous sequence of at least 14 amino acid residues and having the following general sequence (I),
wherein the N-terminal position 1 is located on the left side:
wherein “v” is a variable amino acid residue position,
wherein “+” is a position with a positively charged amino acid residue,
wherein the contiguous sequences of p and p′ are selected from a sequence comprising at least the first 14 amino acids counted from the N-terminus of general Seq. No 1a to general Seq. No 1 m, which may be varied at positions by additional side chain-to-side chain crosslinking amino acids “#”, and possible combinations thereof, or a functional variant thereof having at least 90% identity thereof,
wherein the N-terminal position 1 is located on the left side:
Pos.
1 32
KKQAQRKRHKLNRKERGHKSPSEQRRSELWHA
(Seq. No 1a);
(SEQ ID NO 1)
KKQ#QRKRHK#NRKERGHKSPSEQRRSELWHA
(Seq. No 1b);
(SEQ ID NO 2)
KKQAQR#RHK#NRKERGHKSPSEQRRSELWHA
(Seq. No 1c);
(SEQ ID NO 3)
KKQAQRKRHK#NRK#RGHKSPSEQRRSELWHA
(Seq. No 1d);
(SEQ ID NO 4)
KKQAQRKRHKLNRKERGHKSPSE#RRS#LWHA
(Seq. No 1e);
(SEQ ID NO 5)
KKQAQRKRHKLNRKERGHKSPSEQRRS#LWH#
(Seq. No 1f);
(SEQ ID NO 6)
KKQ#QRKRHK#NRKERGHKSPSE#RRS#LWHA
(Seq. No 1g);
(SEQ ID NO 7)
KKQ#QRKRHK#NRKERGHKSPSEQRRS#LWH#
(Seq. No 1h);
(SEQ ID NO 8)
KKQAQR#RHK#NRKERGHKSPSE#RRS#LWHA
(Seq. No 1i);
(SEQ ID NO 9)
KKQAQR#RHK#NRKERGHKSPSEQRRS#LWH#
(Seq. No 1k);
(SEQ ID NO 10)
KKQAQRKRHK#NRK#RGHKSPSE#RRS#LWHA
(Seq. No 1l);
(SEQ ID NO 11)
and
KKQAQRKRHK#NRK#RGHKSPSEQRRS#LWH#
(Seq. No 1m),
(SEQ ID NO 12)
and
wherein the dimerization motif b comprises a cleavable link and/or wherein the motif b covalently connects the oligonucleotide-binding motifs.

47 more elements

Dependencies are inferred from the claim text.

Facts

Application

19/116,072Filed 29 Sep 2023

Priority

NL 203318529 Sep 2022

Published

23 Jul 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 14/00
Peptides having more than 20 amino acids
C07K 14/001
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: by chemical synthesis
C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
C07K 19/00
Hybrid peptides , i.e. peptides covalently bound to nucleic acids, or non-covalently

Compounds for rna stabilisation and delivery

Life of this patent

Compounds for rna stabilisation and delivery

Life of this patent

Abstract

Claims18